Beispiel: Heart Attack

Suchen Sie in klinischen Studien nach: Sunitinib

Insgesamt 556 ergebnisse

NCT02713763

Abgeschlossen

Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib

Bedingungen: Pancreatic Neuroendocrine Tumour Metastatic
NCT03066427

Abgeschlossen

Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.

Bedingungen: Clear Cell Renal Carcinoma
NCT02626754

Beendet

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Bedingungen: Renal Cell Carcinoma
NCT02398552

Unbekannter Status

A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.

Bedingungen: Metastatic Renal Cell Carcinoma
NCT03905889

Rekrutierung

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

Bedingungen: Renal Cell Carcinoma Metastatic
NCT03449173

Unbekannter Status

Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)

Bedingungen: Type B3 Thymoma; Thymic Carcinoma
NCT01824615

Abgeschlossen

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Bedingungen: Ovarian Cancer; Adverse Effects
NCT01499121

Abgeschlossen

Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

Bedingungen: Clear Cell, Metastatic Renal Cell Carcinoma
NCT01286896

Unbekannter Status

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

Bedingungen: Malignant Solid Tumour
NCT00768144

Abgeschlossen

Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma

Bedingungen: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
NCT04115189

Abgeschlossen

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

Bedingungen: Metastatic Renal Cell Carcinoma ( mRCC)
NCT00961571

Beendet

Sunitinib and Capecitabine for First Line Colon Cancer

Bedingungen: Metastatic Colorectal Cancer
NCT02402062

Abgeschlossen

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Bedingungen: Neuroendocrine Tumors; Pancreatic Neoplasms
NCT01054911

Beendet

Evaluation of Patients With Bulky GIST Using Sunitinib

Bedingungen: Tumor
NCT03140176

Rekrutierung

Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

Bedingungen: Metastatic Renal Cell Carcinoma
NCT00606008

Abgeschlossen

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Bedingungen: Anaplastic Astrocytoma; Glioblastoma
NCT02691793

Rekrutierung

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Bedingungen: Refractory Solid Tumors
NCT01082809

Abgeschlossen

Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma

Bedingungen: Advanced Biliary Tract Adenocarcinoma
NCT00806663

Abgeschlossen

FOLFIRI and Sunitinib in Metastatic Colorectal Cancer

Bedingungen: Metastatic Colorectal Cancer; Liver Metastases
NCT00864721

Abgeschlossen

Sunitinib Non Small Cell Lung Cancer Patients Over 70

Bedingungen: Non Small Cell Lung Cancer
NCT03035630

Zurückgezogen

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Bedingungen: Clear-cell Renal Cell Carcinoma; RCC; Kidney Cancer; Clear-cell Kidney Carcinoma
NCT00967603

Abgeschlossen

Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer

Bedingungen: Pancreatic Cancer
NCT01498835

Abgeschlossen

Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma

Bedingungen: Soft Tissue Sarcoma
NCT03592199

Aktiv, nicht rekrutierend

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

Bedingungen: Clear Cell Renal Cell Carcinoma
NCT00672594

Abgeschlossen

Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy

Bedingungen: Prostate Cancer; Prostatectomy